Reduced quality of life associated adverse events in intermediate hepatocellular carcinoma patients treated with PRECISION TACE with drug eluting beads: Results from the PRECISION V randomized trial

Détails

ID Serval
serval:BIB_2AABE4BDCEF5
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Titre
Reduced quality of life associated adverse events in intermediate hepatocellular carcinoma patients treated with PRECISION TACE with drug eluting beads: Results from the PRECISION V randomized trial
Titre de la conférence
ECR 2010 European Congress of Radiology, Insights into Imaging : education and strategies in European radiology
Auteur(s)
Schernthaner M.B., Lencioni R., Malagari K., Vogl T., Pilleul F., Denys A., Watkinson A., Lammer J.
Adresse
Vienna, Austria, March 4-8, 2010
ISBN
1869-4101
Statut éditorial
Publié
Date de publication
2010
Volume
1
Série
ECR 2010 Book of Abstracts
Pages
S183
Langue
anglais
Résumé
Purpose: To evaluate the extent of quality of life (QoL) associated adverse events
(AEs) following PRECISION TACE with DC Bead compared with conventional
transarterial chemoembolisation (cTACE).
Methods and Materials: 201 intermediate HCC patients were treated with DC
Bead (PRECISION TACE) or conventional TACE (cTACE) with doxorubicin in
the PRECISION V clinical study. 93 patients were treated with DC Bead and 108
Patients with cTACE every 2 months and followed up for 6 months. AEs were classified
according to the South West Oncology Group criteria. QoL associated AEs
were defined as alopecia, constipation, nausea, vomiting, pyrexia, chills, asthenia,
fatigue, and headache.
Results: The biggest difference in QoL associated AEs was for alopecia: 2 patients
(2.2%) for DC-Bead versus 21 patients (19.4%) for cTACE. For other clinical
symptoms, constipation (n=10; 10.8% vs. n=13; 12%), vomiting (n=10; 10.8% vs.
n=14; 13.0%), pyrexia (n=16; 17.2% vs. n=26; 24.1%), chills (n=1; 1.1% vs. n=5;
4.6%), and headache (n=2; 2.2% vs. n=8; 7.4%) showed lower incidence in the
DC Bead group versus cTACE. Nausea, n= 15; 13.9% (n=15; 16.1%) and fatigue,
n=6; 5.6% (n=13; 14.0%) were lower for cTACE. Total dose of doxorubicin was on
average 35% higher in the DC Bead group.
Conclusion: Although patients in the DC Bead group received a higher doxorubicin
dose, less QoL associated AEs were reported for this group. Alopecia, the most obvious
outward sign of toxicity, was only reported in a tenth of DC Bead patients. Thus,
PRECISION TACE with DC Bead improves quality of life associated adverse events.
Création de la notice
01/07/2010 15:05
Dernière modification de la notice
03/03/2018 15:23
Données d'usage